SurinameTuberculosis profile
Population  2015 <1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.014 (0.014–0.015) 2.6 (2.5–2.8)
Mortality (HIV+TB only) 0.011 (<0.01–0.024) 2 (0.54–4.4)
Incidence  (includes HIV+TB) 0.18 (0.14–0.23) 33 (26–42)
Incidence (HIV+TB only) 0.055 (0.042–0.07) 10 (7.8–13)
Incidence (MDR/RR-TB)** 0.024 (0.011–0.037) 4.4 (2–6.8)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.01 (<0.01–0.014) 0.053 (0.027–0.079) 0.063 (0.032–0.093)
Males <0.01 (<0.01–0.011) 0.11 (0.082–0.14) 0.12 (0.087–0.15)
Total 0.018 (0.012–0.024) 0.16 (0.14–0.19) 0.18 (0.14–0.23)
TB case notifications, 2015  
Total cases notified 150
Total new and relapse 144
          - % tested with rapid diagnostics at time of diagnosis 78%
          - % with known HIV status 97%
          - % pulmonary 83%
          - % bacteriologically confirmed among pulmonary 77%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.14 (0.08–0.22)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 42 30%
          - on antiretroviral therapy 26 62%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  14
(5–23)
Estimated % of TB cases with MDR/RR-TB 9.9% (4.1–19) 25% (0.63–81)  
% notified tested for rifampicin resistance 77% 40% 112
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 8, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 77% 146
Previously treated cases, excluding relapse, registered in 2014 33% 12
HIV-positive TB cases, all types, registered in 2014 68% 37
MDR/RR-TB cases started on second-line treatment in 2013   0
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 1.6
Funding source: 57% domestic, 35% international, 8% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data